Last reviewed · How we verify
Immunosuppressive Agents
Immunosuppressive agents inhibit or dampen immune system activation to prevent rejection or reduce autoimmune responses.
Immunosuppressive agents inhibit or dampen immune system activation to prevent rejection or reduce autoimmune responses. Used for Organ transplant rejection prevention, Autoimmune disease management.
At a glance
| Generic name | Immunosuppressive Agents |
|---|---|
| Also known as | Prograf, Cellcept, Immunosuppressive group, Multi-target immunosuppressive therapy, Immunosuppressant, Prednisolone |
| Sponsor | Loma Linda University |
| Drug class | Immunosuppressive agent (class) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is a broad drug class rather than a single entity. Immunosuppressive agents work through various mechanisms including T-cell inhibition (calcineurin inhibitors, mTOR inhibitors), lymphocyte depletion (monoclonal antibodies), or costimulation blockade. They are used to prevent organ transplant rejection and treat autoimmune conditions by reducing pathogenic immune responses.
Approved indications
- Organ transplant rejection prevention
- Autoimmune disease management
Common side effects
- Infection (bacterial, viral, fungal)
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Neurotoxicity
- Malignancy risk
Key clinical trials
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome (PHASE1, PHASE2)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- Study of LYL314 in Aggressive Large B-Cell Lymphoma (PHASE1, PHASE2)
- Fungal Infection Susceptibility
- Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (PHASE2)
- Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy (NA)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |